Hromec A, Okrucká A
I. interná klinika FN, Mickiewiczova, Bratislava.
Bratisl Lek Listy. 1990 Apr;91(4):284-8.
Derangements of hemostasis and hemocoagulation in patients with malignancies are known as paraneoplastic syndrome. Their origin, however, has not been unequivocally established and explained, and data on their occurrence are controversial. Examination of 157 patients with different malignant tumor diseases yielded pathological laboratory findings in 94.2%. The most frequent finding was the state of hypercoagulation in 41.0%; hypercompensated syndrome of disseminated intravascular blood clotting (DIC) was found in 10.9%, compensated DIC syndrome in 18.0%, consumptive coagulopathy in 3.8%, and in 19.2% hypocoagulation state caused by other abnormalities. The laboratory finding was normal only in 5.8% of the patients. In the light of the high occurrence rate of hemostatic and hemocoagulation changes in malignant diseases, established by laboratory analysis, the use of anticoagulants and antiaggregation substances appears to be justified in the majority of cases, both to prevent the development of these changes which may complicate the course of the malignant condition, and in preoperative care to reduce the rate of postoperative thromboses in patients with tumors.
恶性肿瘤患者的止血和血液凝固紊乱被称为副肿瘤综合征。然而,其起源尚未得到明确证实和解释,关于其发生的数据也存在争议。对157例患有不同恶性肿瘤疾病的患者进行检查,94.2%的患者有病理实验室检查结果。最常见的结果是高凝状态,占41.0%;发现10.9%的患者有弥散性血管内凝血(DIC)的高代偿综合征,18.0%的患者有代偿性DIC综合征,3.8%的患者有消耗性凝血病,19.2%的患者因其他异常导致低凝状态。只有5.8%的患者实验室检查结果正常。根据实验室分析确定的恶性疾病中止血和血液凝固变化的高发生率,在大多数情况下使用抗凝剂和抗聚集物质似乎是合理的,这既能预防这些可能使恶性疾病病程复杂化的变化的发生,又能在术前护理中降低肿瘤患者术后血栓形成的发生率。